CLBT · Cellebrite DI Ltd
The AI's read
Cellebrite missed Q2 revenue and cut Q3 and full-year 2026 guidance, with management blaming timing and procurement delays tied to government deals. Shares plunged about 31% to a new 52-week low, so the market punished the execution miss hard. The drop is massive, so much downside is already priced in after the 31.4% collapse and the stock sitting near its 52-week low. Still, the miss and weaker guidance are company-specific and point to sustained revenue pressure from delayed large transactions. Our take leans bearish because execution questions plus lowered guidance increase the odds of further downside despite the sharp repricing. Conviction 84% — the catalyst is idiosyncratic, giving an edge, but the prior move limits asymmetric upside.